International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-6 doi: 10.5281/zenodo.14214118
Original Research Article
Assessment of Maternal and Perinatal Outcomes in Pregnancies with Preterm Premature Rupture of Membranes
Published
Nov. 25, 2024
Abstract

Background: Preterm premature rupture of membranes (PPROM) significantly impacts maternal and perinatal outcomes. This study evaluated outcomes and predictive factors in PPROM cases.Methods: A prospective observational study of 80 women with PPROM between 24 and 36 weeks' gestation was conducted. Maternal and neonatal outcomes were analyzed, and factors affecting latency period were evaluated.Results: The mean gestational age at PPROM was 31.3 ± 3.4 weeks, with a mean latency period of 8.4 ± 4.2 days. Chorioamnionitis occurred in 17.5% of cases. The cesarean section rate was 42.5%, with fetal distress being the primary indication (44.1%). NICU admission was required for 60.0% of neonates, with respiratory distress syndrome affecting 35.0%. Significant correlations were found between latency period and gestational age (r=-0.542, p<0.001), cervical dilatation (r=-0.486, p<0.001), and inflammatory markers (p<0.01). Conclusion: PPROM outcomes are significantly influenced by gestational age and inflammatory markers. Early identification of risk factors may improve management strategies and outcomes.

Recommended Articles
Loading Image...
Volume-5, Issue-6
Citations
1215 Views
444 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved